MetaVia (NASDAQ:MTVA) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of MetaVia (NASDAQ:MTVA) to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $82.50.

MetaVia Trading Up 13.5%

MTVA opened at $9.56 on Friday. The firm has a market cap of $21.03 million, a price-to-earnings ratio of -1.14 and a beta of 0.27. MetaVia has a 12 month low of $6.05 and a 12 month high of $30.25. The stock has a fifty day moving average price of $8.94 and a 200-day moving average price of $8.71.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.86) by $1.32. On average, equities research analysts forecast that MetaVia will post -3.9 EPS for the current year.

Institutional Trading of MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC grew its stake in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the period. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.